Capricor Therapeutics (CAPR) Consolidated Net Income (2010 - 2026)

Capricor Therapeutics' Consolidated Net Income history runs 17 years deep, the most recent figure standing at -$33.9 million for Q1 2026.

• On a quarterly basis, Consolidated Net Income fell 39.15% year-over-year to -$33.9 million in Q1 2026; TTM through Mar 2026 was -$214.9 million, a 15.66% decrease from a year earlier, with the FY2025 full-year figure at -$105.0 million, down 159.58% from the prior year.
• Consolidated Net Income slipped to -$33.9 million in Q1 2026 per CAPR's latest filing, from -$32.1 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at -$1.4 million in Q4 2023 and bottomed at -$131.1 million in Q3 2024.
• The 5-year median for Consolidated Net Income is -$23.1 million (2024), against an average of -$31.3 million.
• Across the five-year window, Consolidated Net Income jumped 81.52% in 2023 and tumbled 1133.65% in 2024, its largest moves.
• Year by year, Consolidated Net Income stood at -$7.4 million in 2022, then soared by 81.52% to -$1.4 million in 2023, then slumped by 430.63% to -$7.2 million in 2024, then slumped by 343.13% to -$32.1 million in 2025, then dropped by 5.85% to -$33.9 million in 2026.
• Per Business Quant, the three latest CAPR Consolidated Net Income figures stand at -$33.9 million (Q1 2026), -$32.1 million (Q4 2025), and -$60.2 million (Q3 2025).